https://doi.org/10.4081/btvb.2024.119
Venous thromboembolism and mortality in patients with hematological malignancies
Submitted: 20 January 2024
Accepted: 15 April 2024
Published: 16 May 2024
Accepted: 15 April 2024
Abstract Views: 501
PDF: 172
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Mortality and venous thromboembolism (VTE) are major risks for patients with hematological malignancies. However, they are commonly underrepresented in major clinical trials of VTE. Treatment decisions are further complicated by the unique characteristics they frequently exhibit, such as thrombocytopenia. In addition to discussing treatment challenges, knowledge gaps, and future directions, our goal in this narrative review is to provide an overview of the epidemiology and risk factors of mortality in patients with hematological malignancies and VTE.
Pulte D, Jansen L, Brenner H. Changes in long term survival after diagnosis with common hematologic malignancies in the early 21st century. Blood Cancer J 2020;10:56.
DOI: https://doi.org/10.1038/s41408-020-0323-4
Hemminki K, Hemminki J, Forsti A, Sud A. Survival in hematological malignancies in the Nordic countries through a half century with correlation to treatment. Leukemia 2023; 37:854-63.
DOI: https://doi.org/10.1038/s41375-023-01852-w
Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol 2017;28:400-7.
DOI: https://doi.org/10.1093/annonc/mdw604
Khorana AA, Francis CW, Culakova E, et al. Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. J Thromb Haemost 2007;5: 632-4.
DOI: https://doi.org/10.1111/j.1538-7836.2007.02374.x
Sorensen HT, Pedersen L, van Es N, et al. Impact of venous thromboembolism on the mortality in patients with cancer: a population-based cohort study. Lancet Reg Health Eur 2023;34:100739.
DOI: https://doi.org/10.1016/j.lanepe.2023.100739
Abdulla A, Davis WM, Ratnaweera N, et al. A meta-analysis of case fatality rates of recurrent venous thromboembolism and major bleeding in patients with cancer. Thromb Haemost 2020;120:702-13.
DOI: https://doi.org/10.1055/s-0040-1708481
Martens KL, Li A, La J, et al. Epidemiology of cancer-associated venous thromboembolism in patients with solid and hematologic neoplasms in the veterans affairs health care system. JAMA Netw Open 2023;6:e2317945.
DOI: https://doi.org/10.1001/jamanetworkopen.2023.17945
Schoen MW, Carson KR, Luo S, et al. Venous thromboembolism in multiple myeloma is associated with increased mortality. Res Pract Thromb Haemost 2020;4:1203-10.
DOI: https://doi.org/10.1002/rth2.12411
Kristinsson SY, Pfeiffer RM, Bjorkholm M, et al. Thrombosis is associated with inferior survival in multiple myeloma. Haematologica 2012;97:1603-7.
DOI: https://doi.org/10.3324/haematol.2012.064444
Bradbury CA, Craig Z, Cook G, et al. Thrombosis in patients with myeloma treated in the Myeloma IX and Myeloma XI phase 3 randomized controlled trials. Blood 2020;136:1091-104.
DOI: https://doi.org/10.1182/blood.2020005125
An N, Zhang L, Gu L, et al. Prognostic significance of thromboembolism in multiple myeloma: a systematic review and meta-analysis. Transl Cancer Res 2023;12:616-23.
DOI: https://doi.org/10.21037/tcr-23-285
Mahajan A, Wun T, Chew H, White RH. Lymphoma and venous thromboembolism: influence on mortality. Thromb Res 2014;133:S23-8.
DOI: https://doi.org/10.1016/S0049-3848(14)50004-7
Kirkizlar O, Alp Kirkizlar T, Umit EG, et al. The incidence of venous thromboembolism and impact on survival in hodgkin lymphoma. Clin Lymphoma Myeloma Leuk 2020;20:542-7.
DOI: https://doi.org/10.1016/j.clml.2020.02.021
Mahajan A, Brunson A, Keegan THM, et al. High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. Leuk Lymphoma 2020;61: 2605-13.
DOI: https://doi.org/10.1080/10428194.2020.1780584
Faiz AS, Sridharan A, Guo S, et al. Risk factors and mortality associated with venous thromboembolism in the elderly US population with acute lymphocytic leukemia. Thrombosis Update 2024;14.
DOI: https://doi.org/10.1016/j.tru.2023.100155
Faiz AS, Guo S, Sridharan A, et al. Venous thromboembolism and acute myeloid leukemia: risk factors and mortality in elderly white, black and Asian patients. Blood Coagul Fibrinolysis 2023;34:345-52.
DOI: https://doi.org/10.1097/MBC.0000000000001226
Poh C, Brunson A, Keegan T, et al. Incidence of upper extremity deep vein thrombosis in acute leukemia and effect on mortality. TH Open 2020;4:e309-e17.
DOI: https://doi.org/10.1055/s-0040-1718883
Chen L, Zheng Y, Yu K, et al. Changing causes of death in persons with haematological cancers 1975-2016. Leukemia 2022;36:1850-60.
DOI: https://doi.org/10.1038/s41375-022-01596-z
Munoz FJ, Mismetti P, Poggio R, et al. Clinical outcome of patients with upper-extremity deep vein thrombosis: results from the RIETE Registry. Chest 2008;133:143-8.
DOI: https://doi.org/10.1378/chest.07-1432
Gussoni G, Frasson S, La Regina M, et al. Three-month mortality rate and clinical predictors in patients with venous thromboembolism and cancer. Findings from the RIETE registry. Thromb Res 2013;131:24-30.
DOI: https://doi.org/10.1016/j.thromres.2012.10.007
Frere C, Farge D, Schrag D, et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated venous thromboembolism: 2022 updated systematic review and meta-analysis of randomized controlled trials. J Hematol Oncol 2022;15:69.
DOI: https://doi.org/10.1186/s13045-022-01289-1
Wang TF, Kou R, Carrier M, Delluc A. Management of catheter-related upper extremity deep vein thrombosis in patients with cancer: a systematic review and meta-analysis. J Thromb Haemost 2024;22:749-64.
DOI: https://doi.org/10.1016/j.jtha.2023.11.017
Wang TF, Delluc A, Cervi A, et al. A survey of clinician perspectives on the management of catheter-related upper extremity deep vein thrombosis in patients with cancer. Thromb Res 2024;233:10-3.
DOI: https://doi.org/10.1016/j.thromres.2023.11.012
Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002;100:3484-8.
DOI: https://doi.org/10.1182/blood-2002-01-0108
Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005;293:715-22.
DOI: https://doi.org/10.1001/jama.293.6.715
Trujillo-Santos J, Nieto JA, Tiberio G, et al. Predicting recurrences or major bleeding in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008;100:435-9.
DOI: https://doi.org/10.1160/TH08-02-0125
Lee AYY, Kamphuisen PW, Meyer G, et al. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA 2015;314:677-86.
DOI: https://doi.org/10.1001/jama.2015.9243
Hsu C, Patell R, Zwicker JI. The prevalence of thrombocytopenia in patients with acute cancer-associated thrombosis. Blood Adv 2023;7:4721-7.
DOI: https://doi.org/10.1182/bloodadvances.2022008644
Carney BJ, Wang TF, Ren S, et al. Anticoagulation in cancer-associated thromboembolism with thrombocytopenia: a prospective, multicenter cohort study. Blood Adv 2021;5: 5546-53.
DOI: https://doi.org/10.1182/bloodadvances.2021005966
Booth S, Haem SN, Desborough M, et al. Platelet transfusion and anticoagulation in hematological cancer-associated thrombosis and thrombocytopenia: the CAVEaT multicenter prospective cohort. J Thromb Haemost 2022;20:1830-8.
DOI: https://doi.org/10.1111/jth.15748
Falanga A, Leader A, Ambaglio C, et al. EHA Guidelines on management of antithrombotic treatments in thrombocytopenic patients with cancer. Hemasphere 2022;6:e750.
DOI: https://doi.org/10.1097/HS9.0000000000000750
Samuelson Bannow BT, Lee A, Khorana AA, et al. Management of cancer-associated thrombosis in patients with thrombocytopenia: guidance from the SSC of the ISTH. J Thromb Haemost 2018;16:1246-9.
DOI: https://doi.org/10.1111/jth.14015
Napolitano M, Valore L, Malato A, et al. Management of venous thromboembolism in patients with acute leukemia at high bleeding risk: a multi-center study. Leuk lymphoma 2016;57:116-9.
DOI: https://doi.org/10.3109/10428194.2015.1046864
Raskob GE, van Es N, Verhamme P, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018;378:615-24.
DOI: https://doi.org/10.1056/NEJMoa1711948
Young AM, Marshall A, Thirlwall J, et al. Comparison of an oral factor xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018;36: 2017-23.
DOI: https://doi.org/10.1200/JCO.2018.78.8034
McBane RD 2nd, Wysokinski WE, Le-Rademacher JG, et al. Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial. J Thromb Haemost 2020;18:411-21.
DOI: https://doi.org/10.1111/jth.14662
Agnelli G, Becattini C, Meyer G, et al. Apixaban for the treatment of venous thromboembolism associated with cancer. N Engl J Med 2020;382:1599-607.
DOI: https://doi.org/10.1056/NEJMoa1915103
Planquette B, Bertoletti L, Charles-Nelson A, et al. Rivaroxaban vs dalteparin in cancer-associated thromboembolism: a randomized trial. Chest 2021.
Schrag D, Uno H, Rosovsky R, et al. Direct oral anticoagulants vs low-molecular-weight heparin and recurrent VTE in patients with cancer: a randomized clinical trial. JAMA 2023;329:1924-33.
DOI: https://doi.org/10.1001/jama.2023.7843
Frere C, Farge D, Schrag D, et al. Direct oral anticoagulant versus low molecular weight heparin for the treatment of cancer-associated thromboembolism: 2021 updated meta-analysis of randomized controlled trials. Blood 2021;138:668.
DOI: https://doi.org/10.1182/blood-2021-150696
Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive summary: antithrombotic therapy for VTE Disease: second update of the CHEST Guideline and expert panel report. Chest 2021;160:2247-59.
DOI: https://doi.org/10.1016/j.chest.2021.07.056
Streiff MB, Holmstrom B, Angelini D, et al. Cancer-associated venous thromboembolic disease, Version 2.2021, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 2021;19:1181-201.
Sanfilippo KM, Moik F, Candeloro M, et al. Unanswered questions in cancer-associated thrombosis. Br J Haematol 2022;198:812-25.
DOI: https://doi.org/10.1111/bjh.18276
Wang TF, Leader A, Sanfilippo KM. Thrombosis and bleeding in hematological malignancy. Best Pract Res Clin Haematol 2022;35:101353.
DOI: https://doi.org/10.1016/j.beha.2022.101353
Mulder FI, Horvath-Puho E, van Es N, et al. Venous thromboembolism in cancer patients: a population-based cohort study. Blood 2021;137:1959-69.
DOI: https://doi.org/10.1182/blood.2020007338
How to Cite
Sanfilippo, K. M., & Wang, T.-F. (2024). Venous thromboembolism and mortality in patients with hematological malignancies. Bleeding, Thrombosis and Vascular Biology, 3(s1). https://doi.org/10.4081/btvb.2024.119
Copyright (c) 2024 The Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.
Most read articles by the same author(s)
- Yishi Tan, Marc Carrier, Nicola Curry, Michael Desborough, Kathryn Musgrave, Marie Scully, Tzu-Fei Wang, Mari Thomas, Simon J. Stanworth, Cancer complicated by thrombosis and thrombocytopenia: still a therapeutic dilemma , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
Similar Articles
- Simon Noble, Patient and public involvement in cancer-associated thrombosis research: necessary or glorified tokenism? , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Kartik Akkihal, Thomas Varkey, James Kelbert, The use of creatine and the development of deep vein thrombosis. A scoping review , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 3 (2024)
- Daniela Tormene, Elena Campello, Chiara Simion, Anna Poretto, Paolo Prandoni, Paolo Simioni, Combined oral contraceptives and the risk of venous thromboembolism carriers of antithrombin, protein C or S deficiency: Sub-analysis of a prospective cohort study , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Licia Iacoviello, Maria Benedetta Donati, Unveiling the “common soil” of cardiovascular disease and cancer , Bleeding, Thrombosis and Vascular Biology: Vol. 4 No. 1 (2025)
- Paolo Simioni, Vittorio Pengo, Paolo Prandoni, Thrombosis and hemostasis at the University of Padua: a reappraisal on the occasion of its 800th year of history , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Rosina Albisinni, Tommaso Marrazzo, Arta Karruli, Sabrina Manduca, Giuseppe Nobile, Nicola Galdieri, Marisa De Feo, Successful treatment of aortic arch mural thrombosis with low-dose, ultra-slow-flow thrombolysis: a case report and literature review , Bleeding, Thrombosis and Vascular Biology: Vol. 1 No. 3 (2022)
- Anna Falanga, Hugo Ten Cate, Bianca Rocca, How to manage antithrombotic treatments in thrombocytopenic patients with cancer. Comments on the European Haematology Association guidelines , Bleeding, Thrombosis and Vascular Biology: Vol. 2 No. 1 (2023)
- Anna Falanga, Benjamin Brenner, Alok A. Khorana, Welcome to the 12th International Conference on Thrombosis and Hemostasis Issues in Cancer! , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. s1 (2024): 12th ICTHIC
- Bianca Clerici, Mariangela Scavone, Gian Marco Podda, Recent advances in classic heparin-induced thrombocytopenia (HIT), autoimmune HIT, spontaneous HIT, and vaccine-induced immune thrombotic thrombocytopenia , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
- Francesco Marongiu, Elvira Grandone, Silvia Marongiu, Antonella Mameli, Doris Barcellona, Stroke in women: anticoagulation in a complicated puzzle , Bleeding, Thrombosis and Vascular Biology: Vol. 3 No. 2 (2024)
You may also start an advanced similarity search for this article.
